139 related articles for article (PubMed ID: 31203059)
1. Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis.
Dong J; Meng X; Li S; Chen Q; Shi L; Jiang C; Cai J
World Neurosurg; 2019 Oct; 130():e236-e243. PubMed ID: 31203059
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
[TBL] [Abstract][Full Text] [Related]
3. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
Xu T; Chen J; Lu Y; Wolff JE
BMC Cancer; 2010 Jun; 10():252. PubMed ID: 20525214
[TBL] [Abstract][Full Text] [Related]
4. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
Lee YP; Jung HA; Lee MS; Choi JW; Kong DS; Seol HJ; Nam DH; Lee JI; Lee SH
J Neurooncol; 2022 Feb; 156(3):541-549. PubMed ID: 35094201
[TBL] [Abstract][Full Text] [Related]
7. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
[TBL] [Abstract][Full Text] [Related]
8. Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma.
Zhukova N; Rajagopal R; Lam A; Coleman L; Shipman P; Walwyn T; Williams M; Sullivan M; Campbell M; Bhatia K; Gottardo NG; Hansford JR
Cancer Med; 2019 Jan; 8(1):40-50. PubMed ID: 30569607
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta-analysis and Systematic Review.
Xu Y; Li Q; Ma HY; Sun T; Xiang RL; Di F
J Clin Pharm Ther; 2020 Dec; 45(6):1363-1371. PubMed ID: 32598559
[TBL] [Abstract][Full Text] [Related]
10. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for Adults with Malignant Glioma: A Systematic Review and Network Meta-Analysis.
Wang W; Shi G; Ma B; Hao X; Dong X; Zhang B
Turk Neurosurg; 2017; 27(2):174-181. PubMed ID: 27337236
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
14. Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
Liu Y; Feng F; Ji P; Liu B; Ge S; Yang C; Lou M; Liu J; Li B; Gao G; Qu Y; Wang L
Clin Neurol Neurosurg; 2018 Jun; 169():64-70. PubMed ID: 29631109
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
[TBL] [Abstract][Full Text] [Related]
16. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
[TBL] [Abstract][Full Text] [Related]
17. Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis.
Chen Y; Guo L; Li X; Liu R; Ren C; Du S
Clin Neurol Neurosurg; 2020 Nov; 198():106239. PubMed ID: 33007724
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
20. Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.
Roux C; Revon-Rivière G; Gentet JC; Verschuur A; Scavarda D; Saultier P; Appay R; Padovani L; André N
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e630-e634. PubMed ID: 33235152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
